BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Pavel
P
Simara
Martina
M
Peterkova
Stanislav
S
Stejskal
Michaela
M
Potesilova
Irena
I
Koutna
Zdenek
Z
Racil
Filip
F
Razga
Tomas
T
Jurcek
Dana
D
Dvorakova
Jiri
J
Mayer
D048868:Adaptor Proteins, Signal Transducing / Q000096:biosynthesis*; D018952:Antigens, CD34 / Q000096:biosynthesis*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides; D005434:Flow Cytometry / Q000379:methods; D016044:Fusion Proteins, bcr-abl / Q000096:biosynthesis* / Q000235:genetics*; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D000068877:Imatinib Mesylate; D020128:Inhibitory Concentration 50; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000378:metabolism*; D008954:Models, Biological; D009687:Nuclear Proteins / Q000096:biosynthesis*; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D015398:Signal Transduction; D016896:Treatment Outcome
D048868:Adaptor Proteins, Signal Transducing; D018952:Antigens, CD34; D000970:Antineoplastic Agents; D001549:Benzamides; C082869:CRKL protein; D009687:Nuclear Proteins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl